Intervention

vorinostat

ClinicalTrials.gov intervention label

Clinical trials22
Recruiting0
Common conditions25
Lead sponsors shown12

Clinical trials

22 shown
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionNCT01249443 · 2013-11-01
TERMINATED
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone TherapyNCT01720602 · 2012-11-01
COMPLETED
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast CancerNCT01695057 · 2012-10-01
WITHDRAWN
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate CancerNCT01174199 · 2012-02-01
TERMINATED
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor TherapyNCT01153672 · 2010-11-01
COMPLETED
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast CancerNCT01084057 · 2010-05-17
COMPLETED
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)NCT01059552 · 2009-12-16
COMPLETED
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the BreastNCT00788112 · 2009-07-01
COMPLETED
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung CancerNCT00798720 · 2008-12-01
COMPLETED
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast CancerNCT00616967 · 2008-05-01
ACTIVE_NOT_RECRUITING
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By SurgeryNCT00662311 · 2008-03-01
TERMINATED
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)NCT00473889 · 2007-05-01
TERMINATED
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung CancerNCT00481078 · 2007-05-01
COMPLETED
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)NCT00423449 · 2007-03-01
COMPLETED
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast CancerNCT00258349 · 2006-08-01
COMPLETED
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast CancerNCT00368875 · 2006-07-01
COMPLETED
Vorinostat in Treating Patients With Progressive Metastatic Prostate CancerNCT00330161 · 2006-03-01
COMPLETED
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast CancerNCT00262834 · 2005-10-01
COMPLETED
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast CancerNCT00132002 · 2005-06-01
TERMINATED
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00138203 · 2005-06-01
COMPLETED
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced CancerNCT00045006 · 2001-07-01
COMPLETED
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyNCT00005634 · 2000-01-01
COMPLETED

Common conditions

Stage IV Breast Cancer7Male Breast Cancer6Recurrent Breast Cancer6Breast Cancer4Recurrent Non-small Cell Lung Cancer3Stage IIIB Non-small Cell Lung Cancer3Stage IV Non-small Cell Lung Cancer3Prostate Cancer2Recurrent Prostate Cancer2Stage II Breast Cancer2Stage IIIB Breast Cancer2Stage IIIC Breast Cancer2Stage IV Prostate Cancer2Unspecified Adult Solid Tumor, Protocol Specific2Adenocarcinoma of the Prostate1Cancer1Carcinoma, Non Small Cell Lung1HIV Infection1Hormone-resistant Prostate Cancer1Leukemia1Locally Advanced Non-small Cell Lung Cancer1Lymphoma1Multiple Myeloma and Plasma Cell Neoplasm1Non-Small Cell Lung Cancer1Recurrent Anal Cancer1

Trial status mix

COMPLETED15
TERMINATED5
ACTIVE_NOT_RECRUITING1
WITHDRAWN1

Phase mix

PHASE111
PHASE211
NA3
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.